This page is intended for Healthcare Professionals.
PREASSEMBLED, PREFILLED SYRINGES1*
REBIJECT II® AUTOINJECTOR2*
REBIF® REBIDOSE® (INTERFERON BETA-1A)3*
*Images shown are not actual size.
Rebif® allows you to adjust the dose to meet individual patient needs without changing therapy.1
PRISMS was not designed to determine differences in efficacy between the 22 mcg and 44 mcg-dose groups. Both doses were shown to be effective vs placebo in the treatment of patients with relapsing forms of MS.‡ The type of adverse events reported for 22 mcg was the same as for 44 mcg and includes, most commonly, flu-like symptoms and injection-site reactions. The incidence of leukopenia and elevated liver function tests observed was lower in patients receiving 22 mcg 3 times weekly.4
†Injections should be taken 3 times weekly and at least 48 hours apart.
‡Mean number of relapses at 2 years was 1.73 and 1.82 for Rebif® 44 mcg and 22 mcg, respectively, vs 2.56 with placebo.
Rebif® should be stored in the refrigerator between 36°F and 46°F (2°C and 8°C). DO NOT FREEZE. If a refrigerator is not available, Rebif® may be stored between 36°F and 77°F (2°C and 25°C) for up to 30 days and away from heat and light.
INDICATION AND IMPORTANT SAFETY INFORMATION
for REBIF® (interferon beta-1a) for subcutaneous injection
Rebif is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
IMPORTANT SAFETY INFORMATION
Contraindication: Rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation.
Depression and Suicide: Use Rebif with caution in patients with depression, a common condition in people with multiple sclerosis. Depression, suicidal ideation, and suicide attempts have been reported to occur with increased frequency in patients receiving interferon compounds, including Rebif.
Hepatic Injury: There have been rare reports of severe liver injury, including some cases of hepatic failure requiring liver transplantation, in patients taking Rebif. Consider the potential for hepatic injury when Rebif is used in combination with other products associated with hepatotoxicity. Monitor liver function tests and patients for signs and symptoms of hepatic injury. Consider discontinuing Rebif if hepatic injury occurs.
Anaphylaxis and Other Allergic Reactions: Anaphylaxis and other allergic reactions (some severe) have been reported. Discontinue Rebif if anaphylaxis occurs.
Injection Site Reactions Including Necrosis: In controlled clinical trials, injection site reactions occurred more frequently in Rebif-treated patients than in placebo-treated and Avonex-treated patients. Injection site reactions including injection site pain, erythema, edema, cellulitis, abscess, and necrosis have been reported in the postmarketing setting with the use of Rebif. Do not administer Rebif into affected area until fully healed; if multiple lesions occur, change injection site or discontinue Rebif until skin lesions are healed. Some cases of injection site necrosis required treatment with intravenous antibiotics and surgical intervention (debridement and skin grafting). Some cases of injection site abscesses and cellulitis required treatment with hospitalization for surgical drainage and intravenous antibiotics. Rotate site of injection with each dose to minimize likelihood of severe injection site reactions, including necrosis or localized infection.
Decreased Peripheral Blood Counts: Decreased peripheral blood counts in all cell lines, including pancytopenia, have been reported in Rebif-treated patients. In controlled clinical trials, leukopenia occurred at a higher frequency in Rebif-treated patients than in placebo and Avonex-treated patients. Thrombocytopenia and anemia occurred more frequently in 44 mcg Rebif-treated patients than in placebo-treated patients. Monitor patients for symptoms or signs of decreased blood counts. Monitoring of complete blood and differential white blood cell counts is also recommended.
Thrombotic Microangiopathy: Cases of thrombotic microangiopathy (TMA), some fatal, have been reported with interferon beta products, including Rebif, up to several weeks or years after starting therapy. Discontinue Rebif if clinical symptoms and laboratory findings consistent with TMA occur and manage as clinically indicated.
Pulmonary Arterial Hypertension: Cases of pulmonary arterial hypertension (PAH) have been reported in patients treated with interferon beta products, including REBIF. Patients who develop unexplained symptoms (e.g., dyspnea, new or increasing fatigue) should be assessed for PAH. If alternative etiologies have been ruled out and a diagnosis of PAH is confirmed, discontinue treatment and manage as clinically indicated.
Seizures: Seizures have been temporally associated with the use of beta interferons, including Rebif, in clinical trials and in postmarketing reports. Monitor for seizures when administering Rebif to patients, particularly those with pre-existing seizure disorders.
Laboratory Tests: New or worsening thyroid abnormalities have developed in some patients treated with Rebif. Thyroid function tests are recommended every 6 months in patients with history of thyroid dysfunction or as clinically indicated.
Adverse Reactions: The most common side effects with Rebif are injection-site disorders, influenza-like symptoms, abdominal pain, depression, elevated liver enzymes, and hematologic abnormalities.
Pregnancy: Epidemiological data do not suggest a clear relationship between interferon beta use and major congenital malformations, but interferon beta may cause fetal harm based on animal studies. Data from a large human population-based cohort study, as well as other published studies over several decades, have not identified an increased risk of major birth defects with exposure to interferon beta products during early pregnancy. Findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta products in pregnancy have been inconsistent.
Lactation: Limited published literature has described the presence of interferon beta-1a products in human milk at low levels. There are no data on the effects of interferon beta-1a on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for REBIF and any potential adverse effects on the breastfed child from REBIF or from the underlying maternal condition.
To report SUSPECTED ADVERSE REACTIONS, contact EMD Serono, Inc. at 1-800-283-8088 ext. 5563 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
References: 1.Rebif® [Prescribing Information]. Rockland, MA: EMD Serono, Inc. 2.Rebiject II [Instructions for Use]. Rockland, MA: EMD Serono, Inc. 3.Rebif® Rebidose® [Instructions for Use]. Rockland, MA: EMD Serono, Inc.4.PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.